EGFR and non-small cell lung carcinoma: In KN‐010,45 patients with NSCLC harboring epidermal growth factor receptor (EGFR) mutations and disease progression after platinum‐based ChT and an EGFR tyrosine kinase inhibitor were eligible and constituted 8.8% of the patients in the pembrolizumab monotherapy arm and 7.6% of the patients in the docetaxel arm.